Organ-on-a-chip company CN Bio has promoted chief business officer Dr Paul Brooks to the position of CEO with immediate effect.
Former CEO Dr David Hughes will continue to work with the company in a consultative role within its scientific advisory board.
CN Bio designs and manufactures single-and multi-organ microphysiological systems.
Having joined the company in May 2022, Dr Brooks was responsible for shaping CN Bio’s commercial business, expansion strategy and overseeing accelerated growth of its PhysioMimix range of MPS, consumables, kits and services.
In this time, CN Bio also doubled the laboratory space dedicated to its contract research services in response to rising demand for its expertise by pharma and BioTech companies.
With over 25 years’ experience in the life science sector, Dr Brooks served as head of business operations & managing director for PerkinElmer’s Horizon Discovery.
He has also held executive positions with Sigma-Aldrich (now Merck KGaA) and Oxford Genetics, helping to drive the latter’s transformation from startup company to commercialisation.
“I would like to thank David for his leadership of CN Bio through a transformational time, and I look forward to working with him as we begin to fully exploit our incredible innovation engine,” he said.
“I am honoured to be appointed CEO at a pivotal time in the company’s, and the industry’s, evolution, as the value of well-characterised microphysiological systems is increasingly recognised to revolutionise therapeutic programmes.
“As we enter 2023, CN Bio is well positioned to build upon its successes so far and enter this exciting next stage of commercial growth and expansion.”
Dr Hughes added: “Since joining the team, Paul has been a driving force for initiating the next phase of CN Bio’s development. His breadth of industry experience, paired with extensive technical expertise, is a huge asset to the company as CEO, and I am confident that he will successfully continue our mission to transform drug discovery.
“My sincere thanks go to the team, who I have worked alongside for 12 years, and I now look forward to supporting CN Bio’s innovation and growth in an advisory role.”